Despite recent setbacks with p53-activating small molecules including the nutlins, the cancer target keeps drug hunters coming back for more. Could immuno-oncology combinations, stapled peptides and targeted degraders unleash the therapeutic potential of the ‘guardian of the genome’? Despite recent setbacks with p53-activating small molecules including the nutlins, the cancer target keeps drug hunters coming back for more. Could immuno-oncology combinations, stapled peptides and targeted degraders unleash the therapeutic potential of the ‘guardian of the genome’?
有人
肯德鸭
寻道图强
浅尝离白
tuanheqi
贰鸟
AireenBeryl531
genomed
8R60d8
王灿灿
Singularity
InfoNinja
JY
SciGPT
鬼见愁
清脆松
美好乐松
彪壮的小玉
研友_ZAVbe8
Liar
皖公网安备34019202002308
